Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Prepaid Assets: 2010-2024

Historic Prepaid Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $2.6 million.

  • Lineage Cell Therapeutics' Prepaid Assets rose 28.17% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 28.17%. This contributed to the annual value of $2.6 million for FY2024, which is 15.88% up from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' Prepaid Assets is $2.6 million, which was up 15.88% from $2.2 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Prepaid Assets ranged from a high of $2.6 million in FY2024 and a low of $1.8 million during FY2022.
  • Over the past 3 years, Lineage Cell Therapeutics' median Prepaid Assets value was $2.2 million (recorded in 2023), while the average stood at $2.2 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Prepaid Assets dropped by 22.25% in 2022 and then rose by 20.57% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Prepaid Assets (Yearly) stood at $2.4 million in 2020, then dropped by 3.37% to $2.4 million in 2021, then declined by 22.25% to $1.8 million in 2022, then grew by 20.57% to $2.2 million in 2023, then grew by 15.88% to $2.6 million in 2024.